Dr. Reddy's Laboratories (RDY) vs Zoetis (ZTS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Dr. Reddy's Laboratories (RDY) has outperformed Zoetis (ZTS) over the past year, losing 12.8% versus a loss of 49.1%. Over five years, RDY leads with a -7.6% price change compared with -63.9% for ZTS. Zoetis is the larger company by market cap ($30.20 billion vs $10.16 billion), about 3.0 times the size, while Dr. Reddy's Laboratories is growing revenue faster (+13.8% vs +2.3%).
On valuation, Zoetis trades at a lower forward P/E (11.2x vs 18.9x for Dr. Reddy's Laboratories). Dr. Reddy's Laboratories offers the higher dividend yield (65.57% vs 2.82%). Zoetis converts more of its revenue into profit, with a net margin of 28.2% versus 17.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RDY | ZTS |
|---|---|---|
| Share price | $12.20 | $73.08 |
| Market cap | $10.16B | $30.20B |
| 1-day change | -0.57% | +2.14% |
| YTD return | -13.11% | -41.92% |
| 1-year return | -12.79% | -49.07% |
| 5-year return | -7.59% | -63.86% |
| P/E ratio (TTM) | 27.73 | 12.02 |
| Forward P/E | 18.94 | 11.17 |
| EPS (TTM) | $0.44 | $6.08 |
| Dividend yield | 65.57% | 2.82% |
| Annual dividend | $8.00 | $2.06 |
| Revenue (latest FY) | $3.81B | $9.47B |
| Revenue growth (YoY) | +13.76% | +2.28% |
| Net income (latest FY) | $663.00M | $2.67B |
| Gross margin | 58.51% | 71.84% |
| Operating margin | 22.09% | — |
| Net margin | 17.40% | 28.23% |
| 52-week high | $15.67 | $148.30 |
| 52-week low | $11.36 | $68.77 |
| Distance from 52-week high | -22.14% | -50.72% |
| Analyst consensus | none | buy |
| Avg. price target upside | +8.36% | +31.36% |
| Average volume | 2.89M | 5.46M |
| Shares outstanding | 832.99M | 413.22M |
| Employees | 27,527 | 14,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Zoetis is about 3.0 times larger than Dr. Reddy's Laboratories by market value ($30.20B vs $10.16B).
- RDY has outperformed ZTS by 36.3 percentage points over the past year.
- Dr. Reddy's Laboratories trades at a higher earnings multiple (27.7x vs 12.0x trailing P/E).
- Dr. Reddy's Laboratories offers a meaningfully higher dividend yield (65.57% vs 2.82%).
- Zoetis is more profitable, keeping 28.2 cents of every revenue dollar as net income versus 17.4 cents for Dr. Reddy's Laboratories.
- Dr. Reddy's Laboratories grew revenue faster in its latest fiscal year (+13.76% vs +2.28%).
About Dr. Reddy's Laboratories
RDY stock →Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 27,527 employees
About Zoetis
ZTS stock →Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 14,500 employees
RDY vs ZTS FAQ
Which is bigger, Dr. Reddy's Laboratories or Zoetis?
Zoetis (ZTS) is larger, with a market capitalization of $30.20B compared with $10.16B for Dr. Reddy's Laboratories (RDY).
Which stock has performed better over the past year, RDY or ZTS?
RDY returned -12.79% over the past 12 months, compared with -49.07% for ZTS (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, RDY or ZTS?
ZTS has the lower trailing P/E at 12.0, versus 27.7 for RDY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Dr. Reddy's Laboratories or Zoetis?
Dr. Reddy's Laboratories has the higher yield at 65.57%, compared with 2.82% for Zoetis.
Are Dr. Reddy's Laboratories and Zoetis in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.